Key result
PAH shares clinical and therapeutic traits with various cancers but no single cancer fully mirrors it.
Why the study?
PAH and cancer share high mortality and complex prognoses, but due to PAH rarity, these parallels may be underrecognized by healthcare stakeholders.
Identifying cancer analogs for PAH highlights its multidimensional complexity and may help healthcare stakeholders better understand its clinical, therapeutic, and resource utilization implications.
Answers are grounded in this paper and cite their sources.
Partial PAH-cancer overlaps warrant no practice changes; leaves open targeted analog research for prognosis and resources.
Pulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses. Due to PAH’s rarity, these parallels may be underrecognized by healthcare stakeholders. This study explored similarities between PAH and cancer across epidemiological, clinical, therapeutic, and healthcare resource utilization (HCRU) considerations. A four-step approach was employed: (1) inclusion/exclusion criteria were applied to identify potential PAH cancer analogs; (2) characteristics for comparison were categorized as epidemiologic, clinical, therapeutic landscape, and HCRU; (3) a targeted literature review extracted data on disease characteristics; (4) a similarity ranking was calculated as the absolute difference between each cancer’s and PAH’s characteristics. Fourteen cancers met the inclusion criteria. Well-differentiated thyroid cancer (WDTC) had the highest number (5) of characteristics closest to PAH. WDTC and medullary thyroid cancer were most similar to PAH in epidemiology; gastrointestinal stromal tumor was most similar in clinical and HCRU characteristics, and anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer and renal cell carcinoma were most similar in therapeutic landscape. Although no single cancer fully mirrors PAH, the identification of multiple analogs underscores PAH’s multidimensional complexity and confirms its overlap with oncological conditions. Cancer analogs could serve as a valuable framework for enhancing recognition of PAH’s clinical, therapeutic, and HRCU implications among healthcare stakeholders.
No takes yet. Share an insight, caveat, or question.
EI-Kersh et al. (2026) studied Patients with pulmonary arterial hypertension (PAH) compared to patients with various cancers meeting specific criteria of FDA-approved treatments and incidence in the United States. Pulmonary arterial hypertension shares key clinical, therapeutic, and healthcare utilization characteristics with various cancers, with well-differentiated thyroid cancer being most similar epidemiologically and gastrointestinal stromal tumor most similar clinically and in resource use, but no single cancer fully mirrors PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: